nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

25.10.2023 | Inflammatory Disorders

Expression of placental growth factor, neuropilin-1, and neuropilin-2 in primary pterygium tissue

verfasst von: Ali Osman Gundogan, Refik Oltulu, Selman Belviranli, Pembe Oltulu

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to evaluate the expression of placental growth factor (PLGF), neuropilin-1 (NP-1), and neuropilin-2 (NP-2) molecules in primary pterygium tissue compared with normal conjunctival tissue.

Methods

The records of 42 patients who underwent excision surgery with autografts for primary pterygium (pterygium group) and 20 patients who underwent conjunctival nevus excision surgery (control group) in the same period were reviewed retrospectively. The samples obtained from the pterygium tissues in the pterygium group and the clean conjunctival tissues adjacent to the nevus in the control group were collected from the archive. Immunohistochemical stains of the primary antibodies—1/100 diluted PLGF, NP-1, and NP-2 (Abcam Cambridge Science Park, UK)—were applied to all groups. Staining intensities and the percentage of positive cells in epithelial, endothelial, stromal, and inflammatory cells were analyzed by an experienced pathologist.

Results

The positivity rates of PLGF and NP-2 expression in epithelial, endothelial, stromal, and inflammatory cells were found to be higher in the pterygium group than in the control group (PLGF: p < 0.001, p < 0.001, p = 0.001, and p < 0.001, respectively; NP-2: p < 0.001 for all). Staining intensities for PLGF and NP-2 were higher in the pterygium group than in the control group (PLGF: p < 0.001, p < 0.001, p = 0.005, and p < 0.001, respectively; NP-2: p < 0.001, p < 0.001, p = 0.001, and p < 0.001, respectively). However, no significant differences were found in any cell type in terms of NP-1 expression positivity rates (p = 0.730, p = 0.121, p = 0.524, and p = 0.624, respectively) or staining intensity (p = 0.716, p = 0.147, p = 0.147, and p = 0.780, respectively).

Conclusion

PLGF and NP-2 levels were found to be higher in pterygium tissue, while there was no difference in NP-1. These results indicate the possible roles of NP-2 and PLGF in primary pterygium.

Di Girolamo N, Chui J, Coroneo MT, Wakefield D (2004) Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res 23(2):195–228. https://doi.org/10.1016/j.preteyeres.2004.02.002CrossRefPubMed

Chui J, Di Girolamo N, Wakefield D, Coroneo MT (2008) The pathogenesis of pterygium: current concepts and their therapeutic implications. Ocul Surf 6(1):24–43. https://doi.org/10.1016/s1542-0124(12)70103-9CrossRefPubMed

Lee DH, Cho HJ, Kim JT, Choi JS, Joo CK (2001) Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 20(7):738–742. https://doi.org/10.1097/00003226-200110000-00013CrossRefPubMed

Aspiotis M, Tsanou E, Gorezis S, Ioachim E, Skyrlas A, Stefaniotou M et al (2007) Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye (Lond) 21(8):1095–1101. https://doi.org/10.1038/sj.eye.6702495CrossRefPubMed

Liang K, Jiang Z, Zhao B, Shen J, Huang D, Tao L (2012) The expression of vascular endothelial growth factor in mast cells promotes the neovascularisation of human pterygia. Br J Ophthalmol 96(9):1246–1251. https://doi.org/10.1136/bjophthalmol-2012-301540CrossRefPubMed

Hoyama E, Viveiros MM, Shiratori C, de Oliveira DE, Padovani CR, Selva D et al (2015) Expression of vascular endothelial growth factor (VEGF) in macrophages, fibroblasts, and endothelial cells in pterygium treated with 5-Fluorouracil. Semin Ophthalmol 30(3):171–176. https://doi.org/10.3109/08820538.2013.835838CrossRefPubMed

Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, Battisti M et al (1997) Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Investig 76(4):517–531PubMed

Bagri A, Tessier-Lavigne M, Watts RJ (2009) Neuropilins in tumor biology. Clin Cancer Res 15(6):1860–1864. https://doi.org/10.1158/1078-0432.CCR-08-0563CrossRefPubMed

Herzog Y, Kalcheim C, Kahane N, Reshef R, Neufeld G (2001) Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech Dev 109(1):115–119. https://doi.org/10.1016/s0925-4773(01)00518-4CrossRefPubMed

10.

Ling S, Liang L, Lin H, Li W, Xu J (2012) Increasing lymphatic microvessel density in primary pterygia. Arch Ophthalmol 130(6):735–742. https://doi.org/10.1001/archophthalmol.2012.293CrossRefPubMed

11.

Fukuhara J, Kase S, Ohashi T, Ando R, Dong Z, Noda K et al (2013) Expression of vascular endothelial growth factor C in human pterygium. Histochem Cell Biol 139(2):381–389. https://doi.org/10.1007/s00418-012-1019-zCrossRefPubMed

12.

Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK et al (2008) Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 13(4):331–342. https://doi.org/10.1016/j.ccr.2008.01.029CrossRefPubMed

13.

Seifert P, Sekundo W (1998) Capillaries in the epithelium of pterygium. Br J Ophthalmol 82(1):77–81. https://doi.org/10.1136/bjo.82.1.77CrossRefPubMedPubMedCentral

14.

Lutty GA, McLeod DS, Merges C, Diggs A, Plouét J (1996) Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol 114(8):971–977. https://doi.org/10.1001/archopht.1996.01100140179011CrossRefPubMed

15.

Marcovich AL, Morad Y, Sandbank J, Huszar M, Rosner M, Pollack A et al (2002) Angiogenesis in pterygium: morphometric and immunohistochemical study. Curr Eye Res 25(1):17–22. https://doi.org/10.1076/ceyr.25.1.17.9959CrossRefPubMed

16.

Jin J, Guan M, Sima J, Gao G, Zhang M, Liu Z et al (2003) Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 22(5):473–477. https://doi.org/10.1097/00003226-200307000-00015CrossRefPubMed

17.

Detorakis ET, Zaravinos A, Spandidos DA (2010) Growth factor expression in ophthalmic pterygia and normal conjunctiva. Int J Mol Med 25(4):513–516. https://doi.org/10.3892/ijmm_00000371CrossRefPubMed

18.

Di Girolamo N, Kumar RK, Coroneo MT, Wakefield D (2002) UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Invest Ophthalmol Vis Sci 43(11):3430–3437PubMed

19.

Chiang CC, Cheng YW, Lin CL, Lee H, Tsai FJ, Tseng SH et al (2007) Cyclooxygenase 2 expression in pterygium. Mol Vis 13:635–638PubMedPubMedCentral

20.

Awdeh RM, DeStafeno JJ, Blackmon DM, Cummings TJ, Kim T (2008) The presence of T-lymphocyte subpopulations (CD4 and CD8) in pterygia: evaluation of the inflammatory response. Adv Ther 25(5):479–487. https://doi.org/10.1007/s12325-008-0056-4CrossRefPubMed

21.

Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D et al (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9(7):936–943. https://doi.org/10.1038/nm884CrossRefPubMed

22.

Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC et al (2013) Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 152(5):1065–1076. https://doi.org/10.1016/j.cell.2013.01.036CrossRefPubMedPubMedCentral

23.

Perelman N, Selvaraj SK, Batra S, Luck LR, Erdreich-Epstein A, Coates TD et al (2003) Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood 102(4):1506–1514. https://doi.org/10.1182/blood-2002-11-3422CrossRefPubMed

24.

Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K (2000) Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 156(5):1499–1504. https://doi.org/10.1016/S0002-9440(10)65021-3CrossRefPubMedPubMedCentral

25.

Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P et al (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7(2):192–198. https://doi.org/10.1038/84643CrossRefPubMed

26.

Lin H, Luo L, Ling S, Chen W, Liu Z, Zhong X et al (2013) Lymphatic microvessel density as a predictive marker for the recurrence time of pterygium: a three-year follow-up study. Mol Vis 19:166–173PubMedPubMedCentral

27.

Favier B, Alam A, Barron P, Bonnin J, Laboudie P, Fons P et al (2006) Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 108(4):1243–1250. https://doi.org/10.1182/blood-2005-11-4447CrossRefPubMed

28.

Yuan L, Moyon D, Pardanaud L, Bréant C, Karkkainen MJ, Alitalo K, Eichmann A (2002) Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129(20):4797–4806. https://doi.org/10.1242/dev.129.20.4797CrossRefPubMed

29.

Tang XL, Sun JF, Wang XY, Du LL, Liu P (2010) Blocking neuropilin-2 enhances corneal allograft survival by selectively inhibiting lymphangiogenesis on vascularized beds. Mol Vis 16:2354–2361PubMedPubMedCentral

30.

Tang X, Sun J, Du L, Du H, Wang L, Mai J, Zhang F, Liu P (2016) Neuropilin-2 contributes to LPS-induced corneal inflammatory lymphangiogenesis. Exp Eye Res 143:110–119. https://doi.org/10.1016/j.exer.2015.10.017CrossRefPubMed

Titel: Expression of placental growth factor, neuropilin-1, and neuropilin-2 in primary pterygium tissue
verfasst von: Ali Osman Gundogan
Refik Oltulu
Selman Belviranli
Pembe Oltulu
Publikationsdatum: 25.10.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 3/2024
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-023-06280-1

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Expression of placental growth factor, neuropilin-1, and neuropilin-2 in primary pterygium tissue

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2024

Circadian rhythm, ipRGCs, and dopamine signalling in myopia

Test-retest repeatability and agreement of the quantitative contrast sensitivity function test: towards the validation of a new clinical endpoint

Pars plana vitrectomy compared to laser treatment alone in young people with type 1 diabetes and mental health diagnoses: a retrospective case control study

Behind the mask: a critical perspective on the ethical, moral, and legal implications of AI in ophthalmology

Nanopore sequencing method for CTG18.1 expansion in TCF4 in late-onset Fuchs endothelial corneal dystrophy and a comparison of the structural features of cornea with first-degree relatives

Correction to: Comparison of corneal measurements in keratoconus eyes with two swept‑source‑optical coherence tomography devices and a Scheimpflug device

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde